The relevance of T cell immunity for the success of tumor-targeted therapy was proven by the depletion of CD8+ T cells or CD4+ T cells in our tumor model as their absence abrogated the efficacy of BRAFi treatment. This evidence concerns the gene CD8A and neoplasm.